In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Candel Therapeutics (CADL – Research Report), with a price target of $11.00. The company’s shares closed yesterday at $1.54.
According to TipRanks, Bernardino is a 5-star analyst with an average return of 17.2% and a 30.95% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Phio Pharmaceuticals, GeoVax Labs, and Aytu BioScience.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Candel Therapeutics with a $10.00 average price target, which is a 549.35% upside from current levels. In a report released yesterday, BMO Capital also maintained a Buy rating on the stock with a $9.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $9.17 and a one-year low of $1.47. Currently, Candel Therapeutics has an average volume of 36.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Candel Therapeutics Inc is a late clinical stage biopharmaceutical company. It is focused on helping patients fight cancer with oncolytic viral immunotherapies.
Read More on CADL:
- Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer
- Candel Therapeutics to host a virtual research and development day
- Candel Therapeutics initiated with a Buy at H.C. Wainwright
- Candel Therapeutics to Host Virtual R&D Day on December 6, 2022
- Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting
